This segment focuses on the research, development, and clinical trials of monoclonal antibodies targeting the neonatal Fc receptor (FcRn). The primary focus is on IMVT-1401, a fully human monoclonal antibody designed to selectively bind to and inhibit FcRn. Research and development activities include preclinical studies, Phase IIa clinical trials for myasthenia gravis (MG) and thyroid eye disease (TED), and Phase II clinical trials for warm autoimmune hemolytic anemia (WAIHA). The technology leverages advanced antibody engineering and immunology to develop targeted therapies. The goal is to improve the lives of patients suffering from autoimmune diseases by reducing the levels of pathogenic IgG antibodies. Market positioning is centered on addressing significant unmet needs in autoimmune diseases, with a competitive advantage in the specificity and efficacy of FcRn inhibition. Future opportunities include expanding the pipeline to other autoimmune indications and exploring combination therapies. Regulatory and clinical aspects involve navigating FDA approval processes and conducting rigorous clinical trials to demonstrate safety and efficacy. Partnerships and collaborations may be formed with research institutions and pharmaceutical companies to accelerate drug development and commercialization.